Ardelyx has hit its primary endpoint for its key asset tenapanor in a phase 3 hyperphosphatemia test—a much needed positive after years of trial setbacks.

Merck has halted a phase 2/3 Alzheimer’s disease trial after an interim analysis found it was destined to fail.

It's been a torrid few days for antiviral drug developer Aviragen as a second phase 2 trial ended in failure, all but decapitating its R&D pipeline.

Incyte will work alone on developing and selling the GITR and OX40 antibody programs that it has been working on with Agenus as the partners retool their…

Gilead has posted upbeat phase 2 data on its next-generation integrase inhibitor bictegravir in HIV patients.

Positive results in a first crop of patients treated with its dementia drug have encouraged Axovant to start preparing for a phase 3 study.

Ferring Pharmaceuticals is funding development of a long-duration peptide drug based on Foresee’s delivery technology.

Johnson & Johnson has outlicensed its portfolio of hypoxia-inducible factor to Cambridge MA-based Akebia as the biotech boosts its early-stage pipeline.

Exactly one month after Daiichi Sankyo decided to shutter its 170-person Indian R&D site the pharma company is swinging the ax again, this time in its…